Surgical resection is recognized
as a mainstay in the therapy of malignant brain tumors. In clinical
practice, however, surgeons face great challenges in identifying the
tumor boundaries due to the infiltrating and heterogeneous nature
of neoplastic tissues. Contrast-enhanced magnetic resonance imaging
(MRI) is extensively used for defining the brain tumor in clinic.
Disappointingly, the commercially available (MR) contrast agents show
the transient circulation lifetime and poor blood–brain barrier
(BBB) permeability, which seriously hamper their abilities in tumor
visualization. In this work, red fluorescent carbonized polymer dots
(CPDs) were systematically investigated with respect to their BBB-penetration
ability. In summary, CPDs possess long excitation/emission wavelengths,
low toxicity, high photostability, and excellent biocompatibility.
CPDs exhibit high internalization in glioma cells in time- and dose-dependent
procedures, and internalized CPDs locate mainly in endolysosomal structures.
In vitro and in vivo studies confirmed the BBB permeability of CPDs,
contributing to the early stage diagnosis of brain disorders and the
noninvasive visualization of the brain tumor without compromised BBB.
Furthermore, owing to the high tumor to normal tissue ratio of CPDs
under ex vivo conditions, our nanoprobe holds the promise to guide
brain-tumor resection by real-time fluorescence imaging during surgery.